Physician profile
Youssef Botros
NPI 1487068094
$3,317.76
in general payments reported to CMS, 2019-2025
22 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.27 · 2020: $445 · 2021: $238 · 2022: $481 · 2023: $578 · 2024: $1,028 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Travel and Lodging: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.91 |
| Travel and Lodging | $814.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $859.83 | 2024 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655, Olympus |
| Abbvie INC. | $796.06 | 2020-2025 | Rinvoq |
| Boston Scientific Corporation | $405.13 | 2019-2023 | Exalt Model D |
| Gilead Sciences, INC. | $226.32 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $148.27 | 2025 | Tremfya |
| Janssen Biotech, INC. | $132.65 | 2022-2023 | Stelara, Remicade, Simponi Aria |
| Ardelyx, INC. | $120.04 | 2023 | Ibsrela |
| Eisai INC. | $112.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.49 | 2020-2025 | Entyvio |
| Genzyme Corporation | $84.04 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.96 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $46.17 | 2022-2023 | Dificid |
| Olympus America INC. | $42.45 | 2022-2025 | Endoclot Phs, Hanarostent Esophagus Tts(Ccc) |
| Ironwood Pharmaceuticals, INC | $42.38 | 2023 | Linzess |
| Capsovision, INC. | $37.08 | 2024 | Capsocam Plus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.43 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $20.95 | 2023 | Sutab |
| Apollo Endosurgery US INC | $17.34 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $15.52 | 2023 | Lockado |
| Phathom Pharmaceuticals, INC. | $15.37 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $14.52 | 2025 | Rezdiffra |
| Celgene Corporation | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.